Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors

Oncology

Volumn 55, Issue 3, 1998, Pages 177-188

  Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Carboplatin; Chemotherapy; Germ cell tumors; High dose therapy; Late toxicity; New drugs; Peripheral blood stem cells; Testicular cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GONADOTROPIN; IFOSFAMIDE; PACLITAXEL;

CARDIOTOXICITY; DRUG ACCUMULATION; GERM CELL TUMOR; HUMAN; MALE; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; TESTIS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG THERAPY; GERMINOMA; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; TESTICULAR NEOPLASMS;

EID: 0031968401     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011854     Document Type: Review

References (68)

1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990;8: 1777-1781.
2. Williams S, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ: Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastin or etoposide. N Engl J Med 1987;316:1435-1440.
3. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, Greco FA: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-391.
4. Bosl GJ, Geller NL, Cirricone C, Vogelzang NJ, Kennedy BJ, Whitmore WF, Vugrin D, Scher H, Nisselbaum J, Golbey RB: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983;43:3403-3407.
5. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA: Prognostic factors for favourable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4:400-407.
6. The Medical Research Council Working Party on Testicular Tumours: Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: Results of a multicenter study. Lancet 1985;1:8-11.
7. International Germ Cell Cancer Collaborative: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
8. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-2932.
9. Roth BJ, Einhorn LH, Greist A: Long-term complications of cisplatin-based chemotherapy for testis cancer. Semin Oncol 1988;15:345-350.
10. Bokemeyer C, Schmoll HJ: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995;13:283-292.
11. Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-476.
12. Vermorken JB, Bokkel Huinink ten WW, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, Kaye SB: Advanced ovarian cancer. Carboplatin versus cisplatin. Ann Oncol 1993;4 (suppl 4):41-48.
13. O'Reilly SM, Rustin GJS, Smith DB, Newlands ES: Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours. Ann Oncol 1992; 3:163-164.
14. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnall M, Bocall SE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7: 1748-1756.
15. Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S: Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 1991;9:62-69.
16. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RTD, Cullen MH, Mead GM, de Wit R, de Mulder PHM, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 1997;15:1844-1852.
17. Bokemeyer C, Köhrmann O, Tischler J, Weissbach L, Räth U, Haupt A, Harstrick A, Schöffski P, Schmoll HJ: A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumours. Ann Oncol 1996; 7:1015-1021.
18. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P, Sheinfeld J, Russo P, Vlamis V, Carey R, Vogelzang NJ, Crawford ED, Bosl GJ: Randomized trial of etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 1993;11:598-606.
19. Tjulandin SA, Garin AM, Mescheryakov AA, Perevodchikova NI, Gorbunova VA, Sokolov AV, Ljubimova NV, Mironova GT, Molchanov GV, Ozols RF: Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 1993;4:633-637.
20. Harstrick A, Caspar J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: Comparison of the antitumor activity of cisplatin, carboplatin and iproplatin against established human testicular cancer cell lines in vivo and in vitro. Cancer 1989;63:1079-983.
21. Saxman SB, Finch D, Gonin R, Einhorn LH: Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin (BEP) in favourable-prognosis germ cell tumours (GCT): The Indiana University (IU) experience (abstract 1143). Proc Am Soc Clin Oncol 1997;16:321a.
22. Nichols CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH: Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 1994; 5(suppl 12):102-108.
23. Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, Bergmann L, Lammerz U, Freund M, Poliwoda H: Cisplatin, etoposide and ifosfamide salvage therapy for refractory or relapsed germ cell carcinoma. J Clin Oncol 1991;9:1549-1555.
24. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: Recent advances and future directions. J Natl Cancer Inst 1992; 84:1703-1709.
25. Nichols CR, Tricot G, Williams S, van Besien K, Loehrer PJ, Roth BJ, Akard C, Hoffman R, Goulet R, Wolff SN: Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7:932-939.
26. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlafer J, Millor E, Bertolucci A, Schacter L, Einhorn LH: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;7:1163-1172.
27. Blijham G: The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer Clin Oncol 1981;17:433-441.
28. Wolff SN, Johnson DH, Hainsworth JD, Greco FA: High dose VP-16-213 monotherapy for refractory germinal malignancies. A phase II study. J Clin Oncol 1984;4:271-274.
29. Mulder POM, de Vries EG, Koops HS, Splinter T, Maas A, van der Gest S, Mulder NH, Sleijfer DT: Chemotherapy with maximally tolerable doses of VP-16-123 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 1988;24:675-679.
30. Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH, Tricot GJ: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992;117:124-128.
31. Levi JA, Toner G: Dose intensive chemotherapy for poor prognosis germ cell malignancies. Int Germ Cell Tumour Conf, Leeds, 1993.
32. Linkesch W, Krainer M, Wagner A: Phase I/II trial of ultrahigh carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed non-seminomatous germ cell tumors (NSGCT) (abstract 600). Proc Am Soc Clin Oncol 1992;11:196.
33. Mandanas RA, Broun ER, Nichols CR, Salzman D, Turns M, Einhorn LH: Phase I/II dose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with autologous marrow support done in tandem for refractory germ cell tumors (GCT) (abstract 747). Proc Am Soc Clin Oncol 1993;12:240.
34. Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 1992; 69:550-556.
35. Motzer RJ, Mazumdar M, Subhash CG, Bajorin DF, Lyn P, Vlamis V, Bosl GJ: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993;85: 1828-1835.
36. Rosti G, Albertazzi L, Salioni R, Pizzocaro G, Cetto GL, Bassetto MA, Marongolo M: High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase two study. Ann Oncol 1992;3:809-812.
37. Margolin K, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G, Tetef M: Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996;14:2631-2637.
38. Broun ER, Nichols CR, Mandanas R, Salzman D, Turns M, Hromas R, Cornetta K, Einhorn LH: Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 1995;16:353-358.
39. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996;14: 1098-1105.
40. Lampe H, Dearnaley DP, Price A, Mehta J, Powles R, Nicholls J, Horwich A: High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur J Cancer 1995;31:717-723.
41. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D: High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 1994; 12:1223-1231.
42. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W: Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 1997;79:161-168.
43. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W: High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638-2645.
44. Chevreau C, Droz JP, Pico JC, Biron P, Kerbrat P, Cure H, Héron JF, Chavalli B, Fargeot P, Kramar A, Bonzy J: Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur Urol 1993;23:213-218.
45. Bokemeyer C, Schmoll HJ: Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). Eur Urol 1993;23:223-230.
46. Bokemeyer C, Harstrick A, Rüther U, Metzner B, Arseniev L, Kadar J, Illiger HJ, Link H, Raichele A, Beyer J, Hossfeld DK, Schmoll HJ: Sequential treatment with high-dose VIP-chemotherapy plus peripheral blood stem cell (PBSC) support in advanced germ cell cancer, (abstract 596). Proc Am Soc Clin Oncol 1995; 14:230.
47. Droz JP, Culine S, Biron P, Kramar A: High-dose chemotherapy in germ cell tumors. Ann Oncol 1996;7:997-1003.
48. Harstrick A, Schmoll HJ, Wilke H, Schöber C, Stahl M, Köhne-Wömpner C, Bokemeyer C, Dölken G, Burk K, Poliwoda H: High-dose epidoxorubicin in refractory or relapsed nonseminomatous testicular cancer: A phase II study. Ann Oncol 1990;1:375-376.
49. Bokemeyer C, Droz JP, Hanauske A, Schröder M, Queisser W, Schmoll HJ: Treatment of relapsed germ cell tumors with vinorelbine: A trial of the phase I/II study group of the association for medical oncology of the German Cancer Society. Onkologie 1993;16:29-31.
50. Soulié, Garrino C, Gastiaburu J, Brienza S, Bensmaine MA, Misset JL, Cvitkovic E: Preliminary results of an oxaliplatin (LOHP)-CDDP association based salvage program in platinum (PT) pretreated germ cell tumors (GCT) (abstract 223). Ann Oncol 1994; 5(suppl 5):128.
51. Moasser MM, Motzer RJ, Khoo K-S, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E: All-trans retinoic acid for treating germ cell tumors. Cancer 1995;76:680-686.
52. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DU, Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279.
53. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991;9:1692-1703.
54. Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cells growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-1524.
55. Motzer RJ, Bajorin DF, Bosl GJ, Reich L, Tong W, Green GA: Paclitaxel (T) containing first-line salvage therapy selected by risk for patients (pts) with germ cell tumors (GCT) (abstract 1146). Proc Am Soc Clin Oncol 1997;16: 322a.
56. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 1994;120:754-757.
57. Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, Lyn P, Fischer P: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277-2283.
58. Bokemeyer C, Beyer J, Rüther U, Harstrick A, Weissbach L, Köhrmann U, Verbeek W, Schmoll HJ: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996;7:31-34.
59. Christou A, Roth B, Fox S, Williams S, Nichols C, Loehrer P, Buday M, Einhorn L: Phase II trial of paclitaxel in refractory germ cell neoplasms (abstract 632). Proc Am Soc Clin Oncol 1996;15:249.
60. Partyka S, Hutchinson L, Amato R: Preliminary results of taxol/cisplatin chemotherapy in patients with refractory or relapsed nonseminomatous germ cell tumor (abstract 1161). Proc Am Assoc Cancer Res 1996;37:169.
61. Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Beyer J, Jonas U, Kanz L: The role of paclitaxel in chemosensitive urological malignancies: Current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 1996;14:354-359.
62. Boyer M, Raghavan D, Harris PJ, Lietch J, Bleasel A, Walsh JC, Anderson S, Tsang CS: Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990;8:21-26.
63. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J: Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992;10:574-579.
64. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ: Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995;31:2229-2238.
65. Boyer M, Raghavan D: Toxicity of treatment of germ cell tumors. Semin Oncol 1992;2:128-142.
66. Vogelzang NJ, Bosl GJ, Johnson K: Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981;95:288-292.
67. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ: Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996;73:1108-1114.
68. Gietema JA, Sleijfer DT, Willemse PHB, Schraffordt Koops H, van Ittersum E, Verschuren WM, Kromhout D, Sluiter WJ, Mulder NH, de Vries EG: Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992;116:709-715.